Mags Portman: The PrEP debate gains momentum

This blog was originally written for BMJ Clinical Evidence and posted on blogs.bmj.com/ce/

Last week saw a landmark shift in the pre-exposure prophylaxis (PrEP) for HIV debate in England. After 18 months of work with key stakeholders-including clinicians, commissioners, and community advocates-NHS England announced that it was no longer able to fund a significant PrEP rollout; the outcome the Clinical Reference Group (CRG) thought that they had been working towards. The rationale given for this late stage decision is that NHS England does not commission HIV prevention. NHS England will be making up to £2m available over the next two years to run a number of early implementer test sites, which local authorities will have to bid to become.

Truvada for use as PrEP was licensed for use in the United States in July 2012. There is evidence from San Francisco that a combination HIV prevention approach, with PrEP treatment as prevention plus condoms and behavioural intervention, is having an impact upon HIV incidence.

Scroll to Top

Canada Post has provided notification of restarting their operations on December 17, 2024. As Canada Post ramps up and stabilizes their services, the BC-CfE will continue the following measures on an interim basis to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory will utilize private courier for delivery of outgoing reports and documents. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy will utilize private courier for delivery of medications. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

Start typing and press enter to search